Oramed Pharmaceuticals Inc (ORMP)

[navyvet]

There is an absolute difference between the results from our company and theirs. If you look at the statistical data presented, they have results that could possibly even push FDA to give emergency use after starting a phase 3. We don't have any data to indicate how well we met the secondary endpoint of the trial. When those numbers are released, we can compare Apple to apples with their numbers. I doubt we will reproduce their numbers however we are focusing on patients with NASH and T2D which I don't believe they were. So we do have different markets possibly between us.